Biomarker associated with irritable bowel syndrome and Crohn's disease

• US 9,732,387 B2
• Filed: 04/03/2013
• Issued: 08/15/2017
• Est. Priority Date: 04/03/2012
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Merchant, Juanita L., Grasberger, Helmut
• Primary Examiner(s): SALMON, KATHERINE D
• Application Number:
  US14/389,961
• Publication Number:
  US 20150065530A1
• Time in Patent Office: 1,595 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: G16H 10/40 for data related to laboratory analysis, e.g. patient specimen analysis
• CPC Class Codes: G16H 50/30 for calculating health indices; for individual health risk assessment
• CPC Class Codes: G16H 70/60 relating to pathologies
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present invention provides compositions and methods for characterizing irritable bowel syndrome. In particular, the present invention provides compositions and methods for determining polymorphisms associated with IBS-D and Crohn'"'"'s disease. The present invention further provides compositions and methods for determining a treatment course of action in subjects with IBS-D and Crohn'"'"'s disease.

Claims

1. A method of treating comprising:

a) obtaining a sample from a human subject;

b) detecting a homozygous polymorphism selected from rs7130929 allele C, rs4537731 allele T, and rs4757610 allele G, in the sample,

c) diagnosing the subject with diarrhea-predominant irritable bowel syndrome (IBS-D) when said homozygous polymorphism is detected in the sample; and

d) treating said subject with an effective amount of a serotonin antagonist medication, wherein said serotonin antagonist medication targets TPH1.

2. The method of claim 1, wherein said medication is LX1031.

3. The method of claim 1, wherein said subject is identified as homozygous for rs7130929 allele C.

4. The method of claim 1, wherein said subject is identified as homozygous for rs4537731 allele T.

5. The method of claim 1, wherein the subject is administered a 5HT3 antagonist.

6. The method of claim 1, wherein the subject is further identified as having a haplotype comprising rs7130929 allele C, rs4537731 allele T, and rs4757610 allele G.